Geron inks $935m Janssen deal after clinical hold lift
This article was originally published in Scrip
Geron will get $35m up front and may earn up to $900m in milestone fees plus royalties on future sales of the telomerase inhibitor imetelstat under the biotechnology company's worldwide license and collaboration agreement with Johnson & Johnson's Janssen Biotech subsidiary.
You may also be interested in...
Janssen is dropping the telomerase inhibitor as imetelstat nears the conclusion of Phase II in myelodysplastic syndrome and myelofibrosis, but Geron has $183m in cash on hand that it will use to take the drug forward on its own in one or both indications.
IPO Edition: Caribou, AbSci and HCW launched initial public offerings, but three firms that were expected to go public during the week of 19-23 July did not, raising the question of whether investors are beginning to pull back from biopharma offerings.
Pfizer agreed to pay up to $2.4bn to share development and commercialization costs for Arvinas’ estrogen receptor degrader, including in combination with Ibrance.